Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel in Actinic Keratosis
NCT02952898Phase 3Completed
- Sponsor
- Balmoral Medical
- Start
- Oct 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of GDC-695 in actinic keratosis (AK), sponsored by Balmoral Medical. Started Oct 2016; status: completed.
02
Drugs
GDC-695
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02952898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952898.